What smart money is saying about Esperion Therapeutics, Inc.
ESPR
No fund has written a full thesis on Esperion Therapeutics, Inc. in our archive, but 1 fund letter reports a position in it, most recently Wasatch Ultra Growth Fund in December 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in Esperion Therapeutics, Inc. on record in the archive was reported in Q4 2025, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2025 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position
- December 2025
“Esperion Therapeutics, Inc. (ESPR) continued its climb following positive developments in the prior quarter.”
Esperion Therapeutics, Inc.
Read the letters behind these Esperion Therapeutics, Inc. positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger